Clinical trialRSSToday
A company called Photopharmics has finished testing a light therapy device called Celeste for Parkinson's disease. The last patient in the large study has completed all their visits. This is an important step toward potentially getting the device approved for patients to use.
WHY IT MATTERSCompletion of this pivotal trial means Celeste light therapy could move closer to FDA approval, potentially offering Parkinson's patients a new non-drug treatment option if results are positive.
Clinical trialRSS2 days ago
A company called Biovie has finished enrolling patients in a study testing a new oral medication called bezisterim for early-stage Parkinson's disease. The medication is being tested as a standalone treatment that patients could take by mouth. The researchers will now analyze all the data collected, with results expected later this year.
WHY IT MATTERSIf bezisterim proves effective in this Phase 2 trial, it could offer Parkinson's patients a new oral treatment option that works alone without requiring combination with other medications.
Clinical trialRSSMay 15
A large clinical trial testing a new Parkinson's disease medication called solengepras has finished enrolling 341 patients. This medication works differently than standard Parkinson's drugs and is being tested alongside regular treatments to see if it helps patients who experience movement problems that come and go throughout the day.
WHY IT MATTERSIf solengepras proves effective in this Phase 3 trial, it could offer Parkinson's patients a new treatment option that works through a different mechanism than current dopamine-based therapies, potentially helping those with motor fluctuations who don't respond adequately to standard medications alone.
Clinical trialRSSApr 24
A new experimental drug called tavapadon from AbbVie helped people with early Parkinson's disease delay or avoid starting levodopa, which is the standard treatment for this condition. In a completed Phase 3 trial called TEMPO-4, most people taking tavapadon long-term did not need to start levodopa, and those already taking it didn't need to increase their dose. This suggests tavapadon could be a helpful new option for managing early Parkinson's symptoms.
WHY IT MATTERSIf approved, tavapadon could allow people with early Parkinson's to delay levodopa therapy, potentially postponing side effects that come with long-term use of this standard medication.
Clinical trialRSSApr 23
Scientists tested a new pill called VQ-101 that can enter the brain and increase levels of a protective protein in people with Parkinson's disease. In early testing, the drug worked in patients both with and without a specific genetic change (GBA mutation). This is an important first step toward potentially helping different groups of Parkinson's patients.
WHY IT MATTERSThis is one of the first oral drugs shown to cross the blood-brain barrier and activate neuroprotective pathways in genetically diverse Parkinson's patients, potentially expanding treatment options beyond GBA-mutation carriers.
Clinical trialRSSApr 22
A company called BlueRock Therapeutics tested a new cell therapy called bemdaneprocel for Parkinson's disease. In a small early-stage trial, patients who received one dose of this therapy showed improvement in their movement symptoms, and these improvements lasted for up to three years. This is promising because it suggests a single treatment might help Parkinson's patients for a long time.
WHY IT MATTERSIf bemdaneprocel continues to show sustained benefits in larger trials, it could offer Parkinson's patients a one-time treatment option instead of daily medications, potentially improving quality of life and treatment adherence.
Clinical trialRSSApr 22
A new medication called Vyalev helped people with Parkinson's disease stop experiencing unwanted, uncontrolled movements (called dyskinesia) when they switched to it from other Parkinson's drugs. In two clinical trials, most people saw these troublesome movements go away within a few months of starting Vyalev. This is good news because dyskinesia is a common side effect that happens after taking Parkinson's medications for a long time.
WHY IT MATTERSIf you have Parkinson's disease and experience dyskinesia from your current levodopa treatment, switching to Vyalev could eliminate these involuntary movements within months rather than managing them as a permanent side effect.